Annex 1 Contamination Control Strategy: Why Gaps Stay Open
Annex 1 Is No Longer New. Why Are So Many Contamination Control Gaps Still Open? GMP Bridge Content Team 28.09.2026 Biopharma The revised EU GMP Annex 1 came into operation in August 2023. Its final deferred requirement, point 8.123, followed in August 2024. This is no longer a new regulation. The implementation deadline is not […]
FDA CMC Flexibilities for Cell and Gene Therapy
FDA gives CGT sponsors more room to tailor CMC development. The opportunity is real, but only when flexibility is supported by science, lifecycle planning and sponsor ownership.
Contamination Control Strategy (CCS) Implementation in Aseptic Biologics Manufacturing
Case Study: Contamination Control Strategy (CCS) Implementation in Aseptic Biologics Manufacturing GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview Contamination Control Strategy (CCS) is now a cornerstone of EU GMP Annex 1 compliance. For biologics manufacturers, gaps in sterility assurance or Environmental Monitoring can lead to failed inspections, product risks, and reputational damage. […]
Reducing Batch Release Time by 40% in Sterile Injectables Manufacturing
Case Study: Reducing Batch Release Time by 40% in Sterile Injectables Manufacturing GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview Batch release time reduction in sterile injectables manufacturing is a persistent challenge for many mid-sized pharma companies. Long release timelines not only block warehouse space and tie up working capital, but also weaken client […]
QMS Implementation for Clinical Biotech Scaling Towards Commercial Manufacturing
QMS Implementation for Clinical Biotech Scaling Towards Commercial Manufacturing GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview Successful QMS implementation for a clinical-stage biotech is one of the most critical steps when preparing for Phase III and commercialization. Without a scalable Quality Management System, compliance risks and inspection findings can delay timelines and damage investor […]
Global Quality Harmonization Program Across Biologics Sites
Global Quality Harmonization Program Across Biologics Sites GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview Quality Management System harmonization is one of the biggest challenges for global biopharma manufacturers. When multiple sites operate with inconsistent processes — from deviations to batch release — the result is inefficiency, compliance risk, and lack of visibility. This […]
Supplier Qualification and Audit Program for a Fill & Finish Manufacturer
Case Study: Supplier Qualification and Audit Program for a Fill & Finish Manufacturer GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview Supplier qualification and audit program in sterile manufacturing are essential to ensure compliance, protect supply continuity, and meet rising regulatory expectations. Without a structured framework, supplier-related issues can cause production delays, increase deviations, […]
Due Diligence Audit for a US Biotech Investor Evaluating a European Acquisition
Case Study: Due Diligence Audit for a US Biotech Investor Evaluating a European Acquisition GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview For investors in biotech and biopharma, a Due Diligence Audit is essential to uncover hidden GMP and operational risks before acquisitions. Weak Quality Systems or unresolved compliance issues can significantly impact valuation and […]
Manufacturing Strategy & Quality Oversight Program for a Clinical-Stage Biotech Using CDMOs
Case Study: Manufacturing Strategy & Quality Oversight Program for a Clinical-Stage Biotech Using CDMOs GMP Bridge Content Team 12.03.2026 Case Study Case Study Overview For clinical-stage biotechs moving toward Phase III, defining a manufacturing strategy and building effective CDMO Quality Oversight are critical. Without structured governance, outsourced operations can cause delays, compliance gaps, and investor concerns. […]
Pre-Approval (PAI) FDA Mock Audits in CAR-T and Viral Vector Manufacturing Sites
Case Study: Pre-Approval (PAI) FDA Mock Audits in CAR-T and Viral Vector Manufacturing Sites GMP Bridge Content Team 11.03.2026 Case Study Case Study Overview FDA inspection readiness is critical for cell and gene therapy manufacturers, where PAIs test both systems and team behavior. This case study shows how GMP Bridge ran PAI-style mock audits at two CGT sites […]